The Delhi High Court addressed key issues in pharmaceutical patent law regarding coverage disclosure and therapeutic efficacy requirements under Section 3(d) in Intra Cellular Therapies v. Controller of Patents. The ruling highlights complexities in how patent claims are assessed in India.
Delhi High Court Revisits Patent Law in Intra Cellular Therapies Case
The Delhi High Court recently revisited significant issues in pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents. The Court examined the distinction between coverage disclosure and the therapeutic efficacy threshold as outlined in Section 3(d) of the Patents Act.
In its ruling, the Court identified shortcomings in the current legal interpretation, particularly in how the patent's coverage is treated as disclosure. This raises concerns over the application of the novelty standard and the absence of a discussion on inventive steps. While the analysis of Section 3(d) included some accurate interpretations, the critiques of patent coverage present implications for future patent applications.
This decision could affect pharmaceutical innovations and patent applications as it re-evaluates how efficacy and coverage are presented. The treatment of these patenting hurdles is crucial for developers attempting to navigate India's patent landscape.
Practitioners should take note of this development, as it signals potential challenges in patent filings related to therapeutic efficacy and coverage, urging a re-evaluation of strategies when seeking patent protection for pharmaceutical inventions.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026) DHC
